Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial-Reference-Cited by-同舟云学术

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial

Published:2017-04-09 Issue:8 Volume:44 Page:873-884
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Ohtsuki Mamitaro¹,Okubo Yukari²,Komine Mayumi¹,Imafuku Shinichi³,Day Robert M.⁴,Chen Peng⁴,Petric Rosemary⁴,Maroli Allan⁴,Nemoto Osamu⁵

Affiliation:

1. Jichi Medical University; Shimotsuke Japan

2. Tokyo Medical University; Tokyo Japan

3. Fukuoka University; Fukuoka Japan

4. Celgene Corporation; Summit New Jersey USA

5. Kojinkai Sapporo Skin Clinic; Sapporo Japan

Funder

Celgene

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.13829/fullpdf

Reference24 articles.

1. Immunology of psoriasis;Lowes;Annu Rev Immunol,2014

2. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database;Kubota;BMJ Open,2015

3. Global epidemiology of psoriasis: a systematic review of incidence and prevalence;Parisi;J Invest Dermatol,2013

4. Consensus guidelines for the management of plaque psoriasis;Hsu;Arch Dermatol,2012

5. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey;Lebwohl;J Am Acad Dermatol,2014

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast;Frontiers in Immunology;2024-08-07

3. Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT;Dermatology and Therapy;2024-05-27

4. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study;The Journal of Dermatology;2024-05-22

5. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis;Dermatology and Therapy;2023-10-06